Lenvatinib-Pembrolizumab Improves Outcomes in Recurrent Endometrial Cancer: KEYNOTE-146/Study 111
Lenvatinib plus pembrolizumab demonstrated promising antitumor efficacy against recurrent endometrial cancer, which led to its FDA approval.
News
Latest News
DLBCL-Type Richter Transformation Associated With Worse Prognosis vs DLBCL
The development of aggressive lymphoma, typically DLBCL, in patients initially diagnosed with CLL is the defining characteristic of Richter transformation.
Hairy Cell Leukemia: Cladribine With Concurrent Rituximab May Improve Outcomes
Rituximab has some single-agent activity in HCL, but there is evidence that it may eliminate MRD when used with cladribine or pentostatin.
Patients With Non-Small Cell Lung Cancer May Be at the Highest Risk for COVID-19
The researchers noted that medical distancing for those with cancer could help prevent the spread of the virus in this highly vulnerable population.
RACE for Children Act Could Substantially Increase Studies of Pediatric Cancer Drugs
An analysis of previously approved novel anticancer agents estimates that more than 78% would have met the RACE for Children Act criteria for pediatric testing.
Second Cancers Pose Significant Mortality Risk in Myeloproliferative Neoplasms
Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
Rationales for Selecting CD19-Targeted Therapy in R/R B-Cell ALL
Due to the possibility of loss of CD19 expression following treatment with a single CD19-targeted approach, patients may become ineligible for the alternative approach.
10-Year Outcomes Similar for H-IMRT, C-IMRT in Prostate Cancer
10-year cumulative incidence of biochemical and/or clinical disease failure no different with C-, H-IMRT.
Induction in Transplant-Eligible Mantle Cell Lymphoma With Rituximab and Cytarabine Added to Rituximab and Bendamustine
The researchers found that high rates of remission could be achieved with induction therapy using rituximab/bendamustine in addition to rituximab/cytarabine.
Brentuximab Vedotin With Bendamustine for Patients With Refractory or Multiple Relapsed Classic Hodgkin Lymphoma
A retrospective analysis found encouraging evidence for the use of BvB in treatment of RR-cHL.
Glyphosate Exposure and Relative Risks of Non-Hodgkin Lymphoma or Multiple Myeloma
Researchers conducted a meta-analysis of 7 studies involving NHL and 3 focused on MM to determine the role of occupational exposure to glyphosate in terms of risk.
Minority of Melanomas With Complete Response to Anti–PD-1 Relapsed After Drug Cessation
More research is needed to define criteria for stopping therapy.
Cancer Organization Asks White House to Waive Cancer-Related Prior Authorizations
Work from home administrative staff may not have capabilities to obtain authorizations.
Young Cancer Survivors Have More Financial, Food Insecurity
Cancer survivors aged 18 to 39 have consistently higher ‘very worried’ levels about retirement, bills.
Expert Opinion on Addressing Psychosocial Needs of Children Receiving CAR-T Therapy
The authors of this article emphasized the importance of actively involving a diverse group of interdisciplinary team members in the psychosocial care of these patients.
Want to read more?
Please login or register first to view this content.
